Gilead Sciences, Inc. and MiroBio, a privately-held UK-based biotechnology company, announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments.
The acquisition will provide Gilead with MiroBio
